Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Leesburg, VA, Sept. 28, 2026 — Inova Blood Donor Services (IBDS) invites the Loudoun County…
Experienced Inova leader brings nearly two decades of clinical and executive leadership to Loudoun Leesburg,…
Leesburg, VA — Inova Loudoun Hospital Mobile Health Services will be providing countywide blood pressure…
David Gordon, MD is a primary care is a primary care physician at Inova 360°…
Inova Schar Cancer is Northern Virginia’s only FACT-accredited health system https://vimeo.com/1158428376 There is an exciting…
More than three years after a stage IV metastatic breast cancer diagnosis, Amy’s scans are…